We have produced antibodies to a variety of hanta and arena viruses including: Andes, Sin Nombre, Machupo, Junin, Sabia, Guanarito and Hantaan. The prototype in this pipeline is Andes virus, a hanta virus of Central and South America that causes rapid death in humans. The U.S. Army has great interest in therapeutic options for Andes. Our Anti-Andes virus biologics project is led by Lead Scientist: Jay W. Hooper, Ph.D. (United States Army Medical Research Institute of Infectious Diseases). We would expect this antibody to be ready for human trials, most likely to be conducted by U.S. Army contacts in Chile, in less than 2 years.
We have generated antibodies against a number of human use targets, including Rabies virus, West Nile virus, Dengue virus, and multiple influenza viruses, as well as the protozoa responsible for malaria, and demonstrated that these antibodies are able to treat the disease both in cell culture and animal models. Reports of some of this work are currently submitted for publication.
We are in the planning stages to develop antibodies against MERS-CoV with Dr. Thomas Voss, Ph.D. at SRI International.
Avianax is a public/private partnership that has developed a "Plug and Play Platform" technology utilizing antibodies purified from goose eggs for the treatment or prevention of infectious diseases as well as certain cancers in humans. We have started to develop antibodies for the pathogens listed below but the possibilities are endless.